Prurigo nodularis: Picking the right treatment

Most patients with localized nodules should receive topical treatment first. But disappointing results or specific findings described here could necessitate additional or alternative options.

**CASE**  A 43-year-old woman arrives at your office with persistent itching on her arms and legs. For some time, she has used moisturizing lotions and herbal preparations suggested by her mother, but they have provided no relief. You note multiple 0.5-to 2-cm firm, excoriated nodules symmetrically distributed on her elbows and knees bilaterally. She has seasonal allergies and a history of childhood asthma. How would you care for this patient?

T reating prurigo nodularis (PN) can be a daunting task for even the most experienced clinician. Prurigo nodules are cutaneous lesions often produced by repetitive scratching—hence the nickname “picker’s nodules”—which may occur as sequelae of chronic pruritus or neurotic excoriations. Thus, PN can be classified as a subtype of neurodermatitis. The nodules can be intensely pruritic, resulting in an itch-scratch cycle that can be difficult to break. In this review, we examine evidence-based therapies for PN.

**Key findings with prurigo nodularis**

Typically, prurigo nodules are firm, hyperkeratotic, pruritic papules or nodules that range in diameter from a few millimeters to several centimeters. The lesions usually have eroded or ulcerated components secondary to repeated excoriation, which can eventually lead to scarring and changes in pigmentation. Patients can have one nodule or hundreds of lesions, depending on disease severity. The lesions tend to be distributed symmetrically and have a predilection for the extensor surfaces of the upper and lower limbs. The abdomen, posterior neck, upper and lower back, and buttocks are also commonly affected, whereas the face, palms, and flexural areas are rarely involved (FIGURE 1).

The differential diagnosis for PN includes dermatitis herpetiformis, scabies, lichen simplex chronicus, hypertro-
Consider obtaining a biopsy of a non-traumatized lesion, which can help uncover scabies, atopic dermatitis, lichenoid drug eruption, or simple xerosis.

Use the diagnostic work-up to focus management decisions

When taking the history, first determine why patients are picking or scratching. If the lesions are pruritic or painful, look for a potential underlying cause of pruritic symptoms. If you identify an underlying dermatologic or systemic condition, treat that disorder first. For example, adequately treating a patient’s atopic dermatitis or hyperthyroidism may quell the pruritic symptoms and potentially make the prurigo nodules more responsive to symptomatic treatment or even obviate the need for such measures.

If treating the underlying cause of PN does not provide adequate relief, or if no cause for pruritic nodules can be found, the nodules may yet respond to symptomatic treatments targeted at decreasing pruritus and inflammation. In contrast, with patients who habitually scratch lesions they describe as non-pruritic, neurotic excoriations could be the source of PN, making the nodules less likely to respond to antipruritic therapies.

Patient insights. Assessing whether patients have insight into their condition is also important. Some patients may be unaware that they are repetitively picking and scratching the affected areas and causing the development and perpetuation of the nodules. In cases associated with an underlying psychiatric component, such as delusional parasitosis, patients often lack insight into their condition and thus may benefit from treatment of psychiatric comorbidities.

On physical exam, try to find lesions that have not been traumatized by patients. They can be useful in uncovering a primary cause, such as scabies, atopic dermatitis, lichenoid drug eruption, or simple xerosis.

If a diagnosis cannot be made clinically, consider obtaining a biopsy of a nontraumatized lesion. Traumatized lesions are typically unrevealing on histopathology. If the clinical assessment of pruritic lesions is indeterminate, laboratory tests that may prove helpful include, but are not limited to, thyroid-stimulating hormone levels, liver function tests, kidney function, a hepatitis panel, and HIV screening.

With severe refractory pruritus in which a primary cutaneous or systemic cause cannot be determined, evaluate for malignancy—especially polycythemia, lymphoma, or multiple myeloma—by ordering liver function tests (including lactate dehydrogenase), a complete blood count with differential, a basic metabolic panel, a chest x-ray, and possibly a serum protein electrophoresis.

Available treatments

If the patient’s pruritic symptoms do not resolve and an underlying cause cannot be determined, direct treatment at decreasing pruritus either locally or systemically. Topical therapies, typically associated with fewer adverse effects, are preferable in localized cases of PN. In more severe, widespread, or recalcitrant disease, systemic agents may be necessary. Typical first-line treatments for PN aimed at decreasing pruritic symptoms include:

- topical antipruritics, such as ointments containing menthol or camphor; topical corticosteroids, with increased efficacy under occlusion as seen with flurandrenolide tape (Cordran tape)
- oral antihistamines, such as promethazine hydrochloride; oral antidepressants, such as doxepin
- intralesional corticosteroids—eg,
triamcinolone acetonide (the concentration used depends on the thickness of the lesion and how well the lesion responded to prior injections)

- a short course of systemic corticosteroids, unless the patient has a comorbid condition that could be exacerbated by rapid tapering of corticosteroids (eg, psoriasis).

For patients with concomitant depression or anxiety, treatment with a selective serotonin reuptake inhibitor or anxiolytic, respectively, may be indicated. With the exception of topical corticosteroids and oral antihistamines, the aforementioned first-line treatments for PN are mostly based on clinical experience and anecdotal success with no studies to support their use. Furthermore, these treatments may be ineffective for many patients. We present our review of several studies in the literature examining potential therapies for PN.

**Topical therapies**

**Calcipotriol vs betamethasone.** A prospective, randomized, double-blind study that ran right/left comparisons of calcipotriol ointment (a vitamin D₃ analog) and betamethasone ointment as treatment for PN in 9 patients showed that calcipotriol and betamethasone were both effective. However, calcipotriol ointment 50 mcg/g was more effective in reducing the number and size of nodules compared with 0.1% betamethasone valerate ointment.

Topical corticosteroids have long been viewed as a first-line therapy for PN. However, given their potential for adverse effects with long-term use, such as skin atrophy, steroid-sparing agents are preferred. Calcipotriol ointment can be useful as both a steroid-sparing and a keratolytic agent, as it inhibits keratinocyte proliferation. Corticosteroids and calcipotriol possess anti-inflammatory and anti-pruritic properties, likely explaining their efficacy in treating PN.

**Pimecrolimus and tacrolimus.** The topical calcineurin inhibitors pimecrolimus and tacrolimus have been used successfully as steroid-sparing agents in treating atopic dermatitis. Their antipruritic effect, likely related to their influence on cutaneous sensory nerve fibers and inhibition of inflammatory cytokines, could also explain their efficacy in treating PN.

A randomized, hydrocortisone-controlled, double-blind phase II trial sponsored by Novartis was designed as a right/left comparison study between pimecrolimus 1% cream and hydrocortisone 1% cream in 30 patients with non-atopic PN. When applied twice daily, each agent decreased pruritic symptoms and resolved scratch lesions to degrees that were statistically significant. However, an intention-to-treat analysis revealed no significant differences between pimecrolimus and hydrocortisone. In a prospective case series of 11 patients with PN, 2 out of 4 patients (50%) receiving tacrolimus 0.1% ointment and 5 out of 7 patients (71%) using pimecrolimus 1% cream experienced a reduction in pruritic symptoms and improvement of lesions by 50% or greater with twice daily application of their assigned calcineurin inhibitor.

Before prescribing topical calcineurin inhibitors, inform patients of the black-box warning issued by the US Food and Drug Administration.
Administration (FDA) regarding the theoretical increased risk of developing cutaneous malignancy and lymphoma. This warning is controversial because in clinical databases, the incidences of malignancy and lymphoma associated with topical calcineurin inhibitors are less than those observed in the general population.\textsuperscript{14}

\textbf{Capsaicin.} Based on a prospective study of 33 patients with PN, topical capsaicin may be an effective treatment if administered 4 to 6 times daily for at least 2 weeks and up to 10 months.\textsuperscript{17} Patients may require up to 0.3\% concentration for total resolution of pruritus. Importantly, capsaicin use may be limited by the high application frequency.

\textbf{Systemic therapies}

\textbf{Fexofenadine and montelukast.} Oral antihistamines have long been used as a first-line treatment for PN. Although clinical experience and anecdotal success support the use of various antihistamines, evidence-based literature exists only for fexofenadine and the leukotriene receptor antagonist montelukast. These oral agents also avoid potential unwanted effects of topical antihistamines, which may sensitize skin and increase the risk of developing allergic contact dermatitis.\textsuperscript{1}

Whereas antihistamines exert their antipruritic effect by blocking histamine H\textsubscript{1} receptors, montelukast decreases pruritic symptoms by antagonizing leukotriene receptors.\textsuperscript{10} In a prospective study of 12 patients with PN receiving fexofenadine 240 mg twice daily and montelukast 10 mg daily for 4 weeks, 9 of the 12 patients (75\%) reported some degree of improvement.\textsuperscript{10} However, 5 of these 9 patients (56\%) achieved only slight improvement. Level of improvement was based on how well the agents reduced the pruritus and lesion number.

\textbf{Naltrexone.} As an opioid antagonist, naltrexone is able to block endogenous opiates from binding to central opioid receptors and causing the sensation of pruritus. Accordingly, oral naltrexone can be used to treat PN, as shown in an open-label clinical trial in which 9 out of 17 patients (53\%) achieved high antipruritic effect, defined as a reduction of pruritic symptoms by at least half.\textsuperscript{18}

When selecting naltrexone to treat PN, prescribe a daily dose of 50 mg for an average of 4.7 months; up to 20 months of treatment may be required. If tachyphylaxis occurs, consider increasing the dose to 50 mg twice a day. Most patients should notice some level of antipruritic efficacy and varying degrees of lesion flattening, softening, or healing. However, exacerbation after therapy discontinuation may occur in 41\% of patients. Adverse medication effects include fatigue, nausea, and dizziness.\textsuperscript{18}

\textbf{Gabapentin and pregabalin.} In response to a report of a case series in which 4 patients with PN responded well to gabapentin,\textsuperscript{19} Mazza et al\textsuperscript{20} conducted a prospective study of pregabalin treatment for 30 patients with PN. Both gabapentin and pregabalin inhibit calcium influx and subsequent excitatory neurotransmitter release, the mechanism by which they likely decrease pruritus in patients with PN.\textsuperscript{20} In the pregabalin study, 23 out of 30 patients (77\%) experienced complete resolution of pruritic symptoms and a reduction of prurigo nodules in number or flattening. The recommended dosage of pregabalin is 25 mg 3 times daily for 3 months, after which time clinical progress is assessed. If a patient is not lesion-free, continue pregabalin at a maintenance dose of 50 mg/d for

---

\textbf{FIGURE 2}

Thalidomide was effective in this case

Thalidomide effectively resolved this patient’s prurigo nodules shown before (left) and after (right) treatment. The typical thalidomide daily dose is 50-100 mg for up to 6 months.
up to 2 years. Adverse effects typically include headache, sedation, and dizziness.20

**When to refer to a dermatologist**

Refer patients to a dermatologist if initial clinical findings suggest a need for further work-up to rule out primary cutaneous diseases, or if the therapies discussed (**TABLE**10,15-20) yield unsatisfactory results. Dermatologists can provide more advanced treatments that require close monitoring, such as phototherapy,21-24 cyclosporine,25 or thalidomide.26-28 Based on multiple case series and case reports, as well as our own personal experience (**FIGURE 2**), thalidomide is efficacious in treating PN. However, thalidomide is typically reserved for cases that are severe and treatment-recalcitrant due to the drug’s high cost, teratogenicity (pregnancy category X), and potentially irreversible peripheral neuropathy.29

**Putting Tx options into practice**

In addition to ruling out potential causes of pruritus and determining the best treatment for each individual with PN, assess for and appropriately treat any psychiatric comorbidities, which are often a psychological component of PN.

**Localized PN.** Start with topical corticosteroids under occlusion for localized PN. To avoid complications of long-term topical corticosteroid use, including dermal atrophy, periodically switch to a steroid-sparing agent, such as calcipotriol ointment or topical pimecrolimus. Less evidence is available to support the efficacy of tacrolimus ointment in PN treatment. Topical capsaicin is not as practical as other topical treatments since it needs to be applied 4 to 6 times daily. Oral antihistamines and montelukast may be added to the therapeutic regimen if there is a chronic pruritic component related to the

<table>
<thead>
<tr>
<th>Medication</th>
<th>Application frequency/dosing</th>
<th>Clinical considerations</th>
<th>SOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone (topical)8,9</td>
<td>0.1% ointment applied twice daily; increased efficacy under occlusion</td>
<td>Avoid prolonged application of high-potency topical steroids; attempt to alternate or substitute with steroid-sparing agents such as calcipotriol or pimecrolimus</td>
<td>B</td>
</tr>
<tr>
<td>Calcipotriol (topical)8</td>
<td>50 mcg/g ointment applied twice daily</td>
<td>May be more efficacious than betamethasone valerate 0.1% ointment</td>
<td>B</td>
</tr>
<tr>
<td>Pimecrolimus (topical)15,16</td>
<td>1% cream applied twice daily</td>
<td>Discuss FDA black-box warning with patients before initiating treatment</td>
<td>B</td>
</tr>
<tr>
<td>Tacrolimus (topical)16</td>
<td>0.1% ointment applied twice daily</td>
<td>Discuss FDA black-box warning with patients before initiating treatment</td>
<td>C</td>
</tr>
<tr>
<td>Capsaicin (topical)17</td>
<td>0.025% to 0.3% strength, applied 4-6 times daily</td>
<td>High application frequency may lead to low compliance</td>
<td>C</td>
</tr>
<tr>
<td>Fexofenadine (oral) and montelukast (oral)10</td>
<td>240 mg fexofenadine twice daily; 10 mg montelukast daily</td>
<td>Dose of fexofenadine used in study was much higher than doses typically prescribed for relief of pruritus</td>
<td>C</td>
</tr>
<tr>
<td>Naltrexone (oral)18</td>
<td>50 mg/d; may need to increase to 50 mg twice daily if patient develops tachyphylaxis</td>
<td>High rate of exacerbation (41%) after therapy discontinuation</td>
<td>C</td>
</tr>
<tr>
<td>Gabapentin (oral)19</td>
<td>900 mg/d for 3 to 4 months; may taper to 300-600 mg/d as a maintenance dose</td>
<td>Higher doses may be needed to achieve therapeutic efficacy</td>
<td>C</td>
</tr>
<tr>
<td>Pregabalin (oral)20</td>
<td>25 mg 3 times/d for 3 months; may taper to 50 mg/d as a maintenance dose</td>
<td>Appears to be more efficacious overall than antihistamines and naltrexone</td>
<td>C</td>
</tr>
</tbody>
</table>

**TABLE**

Evidence-based therapies for prurigo nodularis

*FDA, US Food and Drug Administration; SOR, strength of recommendation.*
lesions themselves or an underlying atopic diathesis fueling the itch-scratch cycle.

- **Widespread or treatment-resistant PN.** Prescribe naltrexone, gabapentin, or pregabalin for more widespread disease or lesions resistant to conservative therapies. If you suspect a primary cutaneous disease as the underlying cause of pruritus or if topical and oral therapies do not achieve the desired therapeutic effect, refer to a dermatologist for further work-up and treatment.

- **How we would manage the case presented in the introduction.** We would start the 43-year-old on topical corticosteroids under occlusion and periodically substitute calcipotriol ointment. (Given the unease that some patients might feel with the black-box warning on topical calcineurin inhibitors, we would likely try calcipotriol ointment as a courtesy before suggesting topical calcineurin inhibitors.) We would also prescribe an oral antihistamine at the start, given that her history of seasonal allergies and childhood asthma increases her chances of having an atopic component causing or exacerbating her disease. However, assessing her response to topical therapies before initiating an oral antihistamine would also be an appropriate strategy.

Unfortunately, PN is typically a chronic and often treatment-resistant disease with disappointing recurrence rates. As we learn more about the pathophysiology of PN, more effective therapies will hopefully emerge to improve the quality of life for these patients.

**References**


**CORRESPONDENCE**

Michael Saco, MD, Department of Dermatology & Cutaneous Surgery, University of South Florida, 13330 Laurel Drive, Tampa, Fl 33612; ms20142018@aol.com